Abstract:OBJECTIVES: The aim of this study was to compare the effect of 2 y of antiretroviral therapy (ART) on the percentage of activated CD38⁺CD8⁺ T cells and human leukocyte antigen (HLA)-DR⁺CD8⁺ T cells, and the expression of the co-stimulatory molecule CD28 on CD4⁺ and CD8⁺ T cells in the peripheral blood of HIV-infected adults, and to assess the use of immune activation markers to predict the virological response to ART in a cohort of HIV-1-infected patients in the north-western part of China.METHODS: We analyzed changes in the CD4⁺ T cell count, viral load, and the percentages of CD38⁺CD8⁺ T cells, HLA-DR⁺CD8⁺ T cells, CD28⁺CD4⁺ T cells, and CD28⁺CD8⁺ T cells in 48 patients with HIV diseases during 2 y of suppressive highly active antiretroviral therapy (HAART). Good virological responders (n = 20) were defined as those who had suppressed and maintained a plasma viral load below the detection limit of the assay for at least 12 months. Poor virological responders (n = 28) were defined as those with a detectable viral load at 6 and 12 months after beginning HAART.RESULTS: Among the 20 good responders, baseline median levels of CD38⁺CD8⁺ T cells were elevated, but had decreased significantly at 24 months of therapy (p < 0.0001). Median levels of HLA-DR⁺CD8⁺ T cells also decreased at 24 months of therapy (p < 0.0001). Levels of expression of CD28⁺CD4⁺ T cells rose steadily to 6 months (p = 0.03), and smoothly reached levels observed among HIV-negative blood donors during the 24 months of therapy (p > 0.05). Levels of expression of CD28⁺CD8⁺ T cells increased at 24 months (p = 0.04). Among the 28 poor responders, median levels of CD38⁺CD8⁺ T cells decreased significantly at 24 months (p < 0.0001). Levels of HLA-DR⁺CD8⁺ T cells also decreased at 24 months (p < 0.001). Levels of CD28⁺CD8⁺ T cells and levels of CD28⁺CD4⁺ T cells increased at 24 months remained unchanged. The percentage of CD38⁺CD8⁺ T cells appeared to provide a sensitive estimate of the overall immune recovery in comparison with the percentage of HLA-DR⁺CD8⁺ T cells, although this lacked specificity for the determination of early virological drug failure and did not appear to be a reliable surrogate for RNA viral load.CONCLUSIONS: We show that HAART can be used successfully in Chinese populations with elevated baseline immune activation markers and that the percentage of CD38⁺CD8⁺ T cells may be an additional parameter to the current criteria for estimating the antiretroviral response with HAART.

Analysis of CD44 and CD95 Expression on CD4+ T Lymphocyte of HIV-1 Infected Subjects after Effective HAART

[Expression of CD38 and HLA-DR on CD8+ T Cells in Pediatric AIDS Patients Receiving Highly Active Antiretroviral Therapy (HAART)].

Impact of Highly Active Antiretroviral Treatment on Expression of HIV-1 Coreceptors and Ligand Levels in Peripheral Blood from HIV-1 Infected Patients in China

The Impact of Highly Active Antiretroviral Treatment on the Blood Profiles of Patients with Acquired Immune Deficiency Syndrome

Study of T Cell subsets and IL-7 protein expression in HIV-1-infected patients after 7 years HAART

Expression of CD127 of T lymphocytes in peripheral blood of patients with HIV-1/AIDS and its clinical significance

Immune reconstitution in HIV-1 infected individuals with long-term highly active antiretroviral therapy

[Expression of Co-Receptor on Different T Lymphocytes Subpopulations after Effective HAART].

Significance of detecting CD4+ CD45RO+ /CD45RA+ CD127+ T cells and related immune regulation in AIDS patients treated with HAART

Study on the application of CD4+ T lymphocyte rapid detection method in treating AIDS

Effect of Long-Term Highly Active Antiretroviral Therapy on Abnormal Immune Activation and Immune Reconstruction in HIV-1 Infected Individuals

Analysis of B cell phenotype and the restoration of antiretroviral therapy in chronic human immunodeficiency virus type 1 infection

[Impact of Highly Active Antiretroviral Therapy on Plasma MCP-1 and MSP in AIDS Patients].

Changes of the CD4+ T lymphocyte counts and viral load of HIV infected individuals in different stages of infection

HIV DNA and immune alteration during successful HAART.

Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression

Characteristics of refined lymphocyte subsets changes in people living with HIV/AIDS during antiretroviral therapy period: An observation from Wuhan, China

Changes and significance of the common γ-chain cytokines after highly active antiretroviral therapy among HIV/AIDS patients

Variation of CD4+T cell number at different baseline cell immunity levels after initiation of HARRT among HIV/AIDS patients

Evaluation of cellular immune responses in HIV-infected people and AIDS patients